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There are currently no FDA-approved therapeutics available to treat Rift Valley fever
virus (RVFV) infection. In an effort to repurpose drugs for RVFV treatment, a library of
FDA-approved drugs was screened to determine their ability to inhibit RVFV. Several
drugs from varying compound classes, including inhibitors of growth factor receptors,
microtubule assembly/disassembly, and DNA synthesis, were found to reduce RVFV
replication. The hepatocellular and renal cell carcinoma drug, sorafenib, was the most
effective inhibitor, being non-toxic and demonstrating inhibition of RVFV in a cell-type and
virus strain independent manner. Mechanism of action studies indicated that sorafenib
targets at least two stages in the virus infectious cycle, RNA synthesis and viral egress.
Computational modeling studies also support this conclusion. siRNA knockdown of
Raf proteins indicated that non-classical targets of sorafenib are likely important for the
replication of RVFV.
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Introduction
Rift Valley fever virus (RVFV) is the causative agent of Rift Valley fever, a zoonotic arthropod-
borne emerging infectious disease endemic to sub-Saharan Africa that has recently spread to parts
of the Arabian Peninsula (Ikegami and Makino, 2011). There is concern that the disease may
be able to spread out of endemic areas and further into Asia and Europe or even as far as the
western hemisphere (Ikegami, 2012; Rolin et al., 2013). In the majority of human cases, patients
are either asymptomatic or experience a mild self-limiting febrile illness. However, some cases can
be potentially fatal with symptoms ranging from hemorrhagic fever, hepatitis, meningoencephalitis
or ocular damage (Ikegami and Makino, 2011). Besides mosquito bite, humans can be exposed
to the virus via the inhalational route through contact with infected animal bodily fluids or with
contaminated carcasses post-mortem. Aerosol exposure is a route of concern for use of RVFV as a
bioweapon (Caroline et al., 2014).
RVFV affects domestic ruminants with severe economic consequences. Pregnant livestock such
as goats, sheep, camels and cattle that contract RVFV experience high rates of spontaneous
abortion. In addition, younger animals that become infected have very high mortality rates
(Nicholas et al., 2014). Due to the potential to be vectored by mosquito species endemic to the
United States (US) (Golnar et al., 2014), importation of viremic livestock (Rolin et al., 2013),
the possibility of its weaponization, the devastating possible economic burden and morbidity
rates, RVFV has been classified as a Category A pathogen and an overlap select agent by
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the National Institutes of Allergy and Infectious Diseases
(NIAID) and the US Department of Agriculture (USDA). There
are currently no FDA-approved vaccines or therapeutics to
prevent or treat RVFV infection in humans or ruminants
(Caroline et al., 2014). Therefore, more research must be done
to develop safe and effective therapeutics to combat this virus.
To address this need, a library of FDA-approved drugs
was screened for efficacy of RVFV inhibition. Candidates were
evaluated based on the magnitude of viral inhibition and cellular
toxicity. Several clusters of drugs with similar pathway or
protein targets were identified including inhibitors of growth
factor receptors, microtubule assembly/disassembly, and DNA
synthesis. One candidate that was able to inhibit virus levels to the
greatest extent with no toxicity was sorafenib. Sorafenib blocks
the autophosphorylation of a number of receptor tyrosine kinases
(RTKs) and inhibits downstream Raf kinases (such as B- and
C-Raf, Roberts and Der, 2007). To further validate the efficacy
of sorafenib against RVFV infection we examined sorafenib
effects in both in vitro and in vivo models. We observed that
sorafenib could decrease RVFV replication by several logs and
increased the survival of mice infected with virulent RVFV strain,
ZH501. Finally, experiments to delineate at what point of the
virus lifecycle sorafenib was affecting and possible mechanism of
inhibition were performed.
Materials and Methods
Cell culture
Vero (ATCC CCL-81) and 293T (ATCC CRL-3216) cells were
grown in Dulbecco’s modified minimum essential medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 1% penicillin/streptomycin and 1% L-glutamine.
Human small airway epithelial cells (HSAECs) (Popova et al.,
2010) were grown in Ham’s F12 containing 10% FBS,
1% penicillin/streptomycin, 1% L-glutamine, 1% non-essential
amino acids (NEAA), 1% sodium pyruvate and 0.1% 1000X
beta-mercaptoethanol (Invitrogen). Huh7 cells were grown in
DMEM containing 1% L-glutamine, 1% NEAA, 10% FBS,
1% penicillin/streptomycin and 1% sodium pyruvate. BHK-J
cells, a BHK-21 derivative (Lindenbach and Rice, 1997) were
maintained in MEM media containing 1% L-glutamine, 1%
penicillin/streptomycin, and 7.5% FBS. BSR-T7/5 cells, a BHK-21
cell clone stably expressing T7 RNA polymerase (Buchholz et al.,
1999), were cultured similarly as BHK-J cells with the addition
of 500µg/mL geneticin. All cell lines were maintained at 37◦C
in humidified 5% CO2. Unless noted otherwise, all cells were
plated at a density of 5.0 × 105 cells cultured in 6-well plates,
2.5×105 cells cultured in 12-well plates, and 1×104 cells cultured
in 96-well plates.
Viruses
Recombinant (r)MP12 virus was rescued by transfection of
BSR-T7/5 cells with the following plasmids: pProT7-M(+),
pProT7-L(+), pProT7-S(+), pT7-IRES-vN, pT7-IRES-vL, and
pCAGGS-vG (Ikegami et al., 2006; Kalveram et al., 2011). To
generate an initial seed stock, cells (seeded at 3 × 106 cells per
75 cm2 flask) were transfected with 4µg each of pProT7-M(+),
pProT7-L(+), pProT7-S(+), pT7-IRES-vN and 2µg each of pT7-
IRES-vL, and pCAGGS-vG using TransIT-LT1 (Mirus). Ratio of
total plasmid DNA amount (µg) to TransIT-LT1 volume (µL)
was kept at 1:3. Complete media without geneticin selection
was used during transfection and subsequent culturing. At 24 h
post transfection, media was removed, cells washed once, and
complete media added back. After an additional 72 h, media
supernatants were collected, clarified by centrifugation (5min,
3000 rpm, 4◦C), aliquoted, and stored at -80◦C. Infectious viral
titers were determined by plaque assay on Vero cells.
To generate the seed stock of rZH548 virus, co-cultures
of 293T and BHK-J cells (1:1 ratio, 3.0 × 105 cells/well)
were transfected with the following plasmids: pHH21-RVFV-vL,
pHH21-RVFV-vM, pHH21-RVFV-vS, pI.18-RVFV-L, and pI.18-
RVFV-N (Habjan et al., 2008). As described above, a 6-well plate
was transfected using TransIT-LT1 reagent combined with 4µg
plasmid DNA mixture (1µg each of the viral RNA plasmids
and 0.5µg each of the viral protein-encoding plasmids) per well.
Media supernatants for individual wells were collected and viral
titers determined by plaque assay on Vero cells.
To generate a P1 viral stock, subconfluent monolayers of Vero
cells were infected at a multiplicity of infection (MOI) 0.1 for 1 h.
Inoculum was then removed, cells washed once, and complete
media added. Two days later when cytopathic effect was observed
within the culture, media supernatants were harvested twice
and stored at 4◦C. After the last collection, supernatants were
then pooled together, filtered (0.2µM), and stored at −80◦C in
aliquots. Viral titers were determined by plaque assay on Vero
cells.
RVFV ZH501 was obtained from Stuart Nichol, Centers for
Disease Control and Prevention. Upon receipt, the virus was
passaged once in Vero cells and sucrose purified prior to use in
mouse experiments.
FDA-approved Drug Libraries and Treatment
A library of FDA-approved drugs was purchased from
Selleckchem (# L1300) and used for in vitro studies. Drugs
were received resuspended in DMSO at 10mM. The drugs were
further diluted to a concentration of 10µM in culture media for
use in in vitro experiments. Sorafenib tosylate used for in vitro
studies was also purchased from Selleckchem (# S1040) while
sorafenib tosylate used for in vivo studies was purchased from
Eton Bioscience Inc. (# 1100205002). Curcumin (Sigma) was
used at 10µM. For all inhibitor treatments, cells were pretreated
for 1 h before RVFV infection. After viral inoculum was removed
and cells washed, new media containing inhibitor was placed
back on cells. Unless noted otherwise, cells were cultured for
an additional 24 h. As a control, DMSO alone was included for
comparison.
Luciferase Assays
Cells plated in a 96-well plate were infected with RVFV MP12
1NSs-Luc (MP12 lacking the NSs gene and replaced by a gene
encoding Renilla luciferase) at a MOI 0.1 for 1 h. The inoculum
was then removed; cells were washedwith phosphate buffer saline
(PBS) and further cultured in complete media. At the indicated
time point, lysates were harvested using the Renilla-Glo™
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Luciferase Assay System (Promega) as per vendor’s protocol.
Luciferase signal was detected via luminescence detection using
the DTX 880 multimode detector (Beckman Coulter).
Cell Viability Assays
Cell viability assays were performed on drug-treated cells
using CellTiter-Glo Cell Luminescent Viability Assay (Promega)
according to vendor’s instructions. This assay measures relative
ATP levels. Viability was detected via luminescence detection
using the DTX 880 multimode detector (Beckman Coulter) and
percent viability was calculated relative to the DMSO control.
Viral Kinetics
Extracellular supernatants were collected from DMSO, sorafenib
and siRNA treated samples at various times post-infection.
Infectious viral titers were determined by plaque assay on Vero
cells (Baer and Kehn-Hall, 2014).
Intracellular RNA was extracted using the RNeasy
Mini Kit (Qiagen) according to manufacturer’s protocol.
Extracellular RNA was extracted from supernatants using the
MagMAX™−96Viral RNA Isolation Kit (Life Technologies)
according to manufacturer’s protocol. Absolute quantification
of RVFV genomic copies was determined by RT-quantitative
(q)PCR as previously published (Shafagati et al., 2013).
Intracellular Infectivity Assay
To determine intracellular infectious RVFV, 1.0 × 106 HSAECs
and Huh7 cells were plated in 6-well plates. Drug treatments
and rMP12 infections were performed as described above.
Extracellular media supernatants were clarified by centrifugation,
while cells were trypsinized and washed twice in complete media.
Both media supernatants and cell pellets were stored at −80◦C
until use. Cell pellets were thawed and resuspended in 500µl of
complete DMEM media. Cells were then lysed by four freeze-
thaw cycles and centrifuged at 6000 rpm for 5min to remove
cellular debris. Titers of extra- and intracellular supernatants
were determined by plaque assay. After determining the total
extra- and intracellular infectivity for the well, the data were
plotted as the percent intracellular infectivity of the total (i.e., of
both extra- and intracellular supernatants).
siRNA knockdowns
HSAEC cells, at approximately 70% density in 12-well plates,
were transfected with SMARTpool siRNAs targeting B-Raf
(10 nM; Dharmacon, #M-003460-03-0005), C-Raf (10 nM;
Dharmacon, # M-003601-02-0005), a combination of both
(20 nM), or negative control siRNA (10 or 20 nM). All
transfections were performed using Dharmafect 1 reagent
(Thermo scientific, # T-2001-02). An untreated control with
Dharmafect 1 reagent alone was also performed. After 24 h,
transfection media was replaced with complete media and
cultured for additional 24 h before infection. Protein lysates and
extracellular media supernatants were collected at 24 hpi (or 72 h
post siRNA transfection). Protein expression was measured by
western blot analysis and infectious titers determined by plaque
assay.
Western Blots
At 24 h post-infection, cells were collected for western blot
analysis. Media was removed, cells washed with PBS, lysed with
Blue Lysis Buffer [Mixture of 20ml T-PER reagent (Thermo
Scientific Pierce), 30ml 2× Tris-glycine SDS sample buffer
(Invitrogen), 1.3ml 1M DTT, 200µl 0.5M EDTA pH 8.0, 80µl
0.1M Na3VO3, 400µl 0.1M NaF and 1 complete protease
inhibitor cocktail (1 × Halt cocktail, Pierce] and boiled for
10min. Western blot analysis were performed as previously
described (Austin et al., 2012). In brief, membranes were
incubated with primary antibodies against B-Raf (1:1000; Abcam
# ab117860), C-Raf (1:1000; Abcam # ab124452), or actin, diluted
in blocking buffer (PBS containing 3% milk and 0.1% Tween-20)
overnight, 4◦C. Next day, blots were incubated with appropriate
secondary antibodies conjugated to HRP, goat anti-rabbit IgG
or goat anti-mouse IgG (1:1000; Thermo Scientific; #32460
(rabbit), # 2430 (mouse) in blocking buffer).
Animal Studies
For sorafenib toxicity experiments, 6–8 week old female BALB/c
mice were obtained from Harlan Laboratories. Groups of 3 mice
were treated by oral gavage with solvent control (1:4 dilution
of 50% ethanol, 50% Kolliphor EL (Sigma-Aldrich, # C5135) in
sterile water) or with sorafenib (20 or 40mg/kg) daily for 10 days.
Animals were weighed daily and survival and body condition was
monitored for 14 days.
For RVFV infection experiments, 6–8 week old female BALB/c
mice were obtained fromHarlan Laboratories. Groups of 10 mice
were infected with 1 × 103 pfu RVFV ZH501 by sub-cutaneous
injection. Mice were pretreated 2 h prior to infection, and each
day post infection with 30mg/kg of sorafenib or solvent control
via oral gavage for a total of 10 doses. Body condition was
monitored for 14 days post challenge.
All toxicity experiments were carried out in animal bio-
safety level 2 (BSL-2) facilities, and ZH501 infection experiments
in BSL-3 facilities, in accordance with the National Research
Council’s Guide for the Care and Use of Laboratory Animals and
under GMU IACUC protocols.
Computational Model
A computational model of RVFV infection was developed and
analyzed using R Statistical Software (http://www.r-project.org/).
Virus titers over time were approximated using the deSolve add-
on package and the lsoda function. The aim was to develop the
model for the natural infection (without sorafenib) and then use
the model to examine potential anti-viral mechanisms associated
with sorafenib.
The computational model was a 4-dimentional non-linear
system of ordinary differential equations (see Equations 1–4).
This model is a simplified version of a computational model
developed to study influenza A infection (Handel et al., 2010).
This model has four variables, uninfected HSAECs (U), early
infected cells which are unable to produce virus (E), virus
producing HSAECs (I), and virus produced (V). A schematic of
the model is shown in Figure 6B. As shown, naïve uninfected
HSAECs (U) replicate at some basal rate, g, and become infected
at rate b. Infection immediately converts an uninfected HSAEC
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into an infected HSAEC, but importantly these newly infected
HSAECs are not able to produce virus particles until after some
delay, l. For this reason, newly infected (but non-virus producing)
HSAECs are referred to as early infected (E) and the delay
time (i.e., lag) require to convert these cells into infected virus-
producing HSAECs (I) is l. Thereafter, I produce virus (V) at
some rate, p, and die at some rate d. Finally, newly formed virus
can re-infect thereby creating the dynamics seen in this tissue
culture infection model.
dU
dt
= gU − bUV (1)
dE
dt
= bUV − lE (2)
dI
dt
= lE− dI (3)
dV
dt
= pI − bUV (4)
To estimate initial conditions (which are summarized in Table 1,
5.20 × 104 pfu/ml were added to each well and incubated for
1 h. Thereafter, wells were washed twice and, as discussed above,
viral titers in the pooled wash were quantified. Here, there was
1.86 × 104 pfu/ml in the wash, suggesting 3.34 × 104 pfu/ml
remained in the well at the start of the infection. In addition, it
was estimated that the number of HSAECs in each well at the
time of infection was 1.67 × 105 HSAECs/ml. Thus, assuming
a well-mixed system (i.e., each HSAEC was infected with a single
virus particle), there were 1.34×105 uninfected HSAECs (U) and
3.34× 104 early infected HSAECs (E). For the other two variable
initial conditions, we make the assumption that there were zero
virus-producing HSAECs (I) at time 0 and because of this there
are no viruses present at time 0 [i.e., V(0) = 0].
For model parameter estimates (also summarized in Table 1),
the number of HSAECs in a group of control wells were
quantified at 0 and 24 h and were determined to be 1.67 × 105
HSAECs/ml and 1.70×105 HSAECs/ml, respectively. These data
were fit to a simple exponential growth model where the growth
rate, g, was estimated at 0.742×10−3/h. The infection rate, b, was
estimated at 0.195/h/U, which was derived by noting that during
the 1 h initial infection in a well with 1.67× 105 HSAECS, 3.34×
TABLE 1 | Model parameters and initial conditions estimated from data.
Symbol Meaning Value
g Growth rate of uninfected HSAECs 0.742× 10−3 h−1
b Infection rate of uninfected HSAECs 0.195 h−1 U−1
1/l Delay (lag) time from infection to virus
production
0.25 h−1 (4 h lag)
d Death of virus-producing HSAECs 0.222× 10−1 h−1
p Virus production rate 0.531 h−1
U(0) Initial uninfected HSAECs 1.34× 105 HSAECs ml−1
E(0) Initial early (non-virus producing)
HSAECs
3.34 104 HSAECs ml−1
I(0) Initial infected (virus producing)
HSAECs
0 HSAECs ml−1
V(0) Initial virus numbers 0 PFU ml−1
104 early infected HSAECs (E) were produced [i.e., 3.34 × 104
/(1∗1.67 × 105) = 0.195]. For viral production rate, p, the 4–
16 h pfu/ml data from Figure 5A were fit to a simple exponential
growth model where the rate was estimated at 0.531/h. Virus-
induced HSAEC death was estimated from data where there was
1.67 × 105 HSAECS/ml at 0 h and 9.77 × 104 HSAECS/ml at
24 h after infection. These data were fit to a simple exponential
decay model were d was estimated at 2.22 × 10−2/h. Finally,
the time it takes for an early infected HSAEC (E) to become a
virus-producing HSAEC (I) was estimated at 4 h (Figure 5A);
l = 0.25/h.
Statistics
Statistical significance was determined using Student’s unpaired
t-test to compare the means of test vs. control data. Differences
between test and control data were deemed statistically
significant if the two-tailed p value was ≤ 0.01. For determining
CC50 and EC50 values, data was plotted using Prism (GraphPad)
using non-linear regression analysis. For the intracellular
infectivity assay, Two-Way analysis of variance (ANOVA)
was performed using the Holm-Sidak correction for multiple
comparisons.
Results
FDA-approved Drug Screening
In order to determine which of 420 FDA-approved drugs were
effective at inhibiting RVFV infection, a high throughput assay
was first optimized. The reporter virus, RVFV MP12-Luc, which
encodes for Renilla luciferase in place of NSs (a non-structural
protein that is not essential for virus replication), was utilized
to measure virus replication. Vero cells were left untreated or
pre-treated with DMSO or curcumin for 1 h prior to infection.
Curcumin was used as a positive control for inhibition, since
it has been shown to decrease RVFV infection (Narayanan
et al., 2012). After pre-treatment, cells were infected with
MP12-Luc at a MOI of 0.1, 1.0 or 10. One hour following
infection, media containing the respective treatment was added
back and cells cultured until 24 h post-infection (hpi). At this
time, cells were lysed and relative luminescence determined. In
both untreated and DMSO samples, there was an increase in
luminescence relative to MOI. As expected, curcumin treatment
decreased RVFV infection to levels that were almost undetectable
(Figure 1). Z′ factors were calculated for each of the MOIs tested.
The Z′ factor is used to assess the quality of an assay in order
to predict if it would be useful in a high-throughput setting. A
Z′ factor of 1.0 is ideal and cannot be exceeded; between 0.5
and 1.0 denotes an excellent assay; between 0 and 0.5 denotes a
marginal assay; and a Z′ factor less than 0 indicates that there is
too much overlap between the positive and the negative controls
for the assay to be useful (Zhang et al., 1999). Based on our results,
the condition chosen for the high-throughput assay was MOI
0.1 since infection at this MOI resulted in the highest Z′ factor
(Z′ = 0.89).
Using this luciferase reporter assay, a library of FDA-approved
drugs was screened. The library comprised of a diverse range
of compounds related to oncology, cardiology, inflammation,
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FIGURE 1 | RVFV luciferase assay development. Vero cells were either
untreated or preincubated with DMSO or 10µM curcumin for 1 h prior to
infection with MP12 1NSs-Luc (MOI 0.1, 1.0, or 10). After 1 h infection, virus
inoculum was removed, cells washed and media containing respective
treatments was added back to cells. Twenty-four hours post infection (hpi),
luciferase activity was measured and graphed in relative luminescence units
(RLU). The average and standard deviation of three biological replicates are
plotted.
immunology, neuropsychiatry and analgesia among others. Each
drug was used at a concentration of 10µM to pre-treat Vero
cells in a 96-well format. Following pre-treatment the cells were
infected with MP12-Luc at a MOI 0.1. Virus inoculum was
removed and complete media containing the respective drug
was added back to the cells and left on for 24 h. At this time,
luciferase reporter activity was measured (Table S1). Compounds
that were most efficacious at inhibiting RVFV activity (50%
inhibition or greater) were retested in triplicate (Table S2). In
addition, cell viability assays were performed to ensure that
inhibitory phenotypes were not associated with drug-related
toxicity (Table S3). Table 1 lists the compounds that significantly
reduced Renilla luciferase reporter activity (p ≤ 0.01) while
maintaining cell viability (≥80%). Some of the classes of drugs
that were successful at inhibiting RVFV replication included
growth factor receptor inhibitors, microtubule modulators and
synthetic estrogen receptor modulators among others. Through,
the luciferase reporter assay, it was determined that sorafenib
tosylate (sorafenib) was able to reduce RVFV replication with
the greatest efficacy, causing a 93% reduction in luciferase
luminescence with no toxicity (Table 2).
Sorafenib Reduces RVFV Replication in Multiple
Cell Types
To further validate the ability of sorafenib to inhibit RVFV
in a variety of cell backgrounds Vero, HSAEC, or Huh7 cells
were examined (Figures 2A–C respectively). Cells infected with
rMP12 were pre- and post-treated and infectious titers at 24
hpi were determined by plaque assay. The level of infectious
rMP12 virus was significantly reduced by approximately 2–3 logs
depending on cell type, confirming that the inhibitory effect of
sorafenib was not cell type specific. In addition, BSL-3 RVFV
strain ZH548 levels were significantly reduced by close to 4
logs, reaffirming the ability of sorafenib to inhibit RVFV in vitro
(Figure 2D).
Selectivity Index of Sorafenib
Selectivity indices (SI) are important measurements in
determining the therapeutic potential of an antiviral drug. The
SI is defined as the ratio of cytotoxic concentration 50 (CC50) to
effective concentration 50 (EC50) for each compound. To find the
CC50 for sorafenib, cell viability assays were performed. Two-fold
serial dilutions of sorafenib from 160 to 0.625µM were tested
and even at the highest concentration analyzed, viability was not
greatly impacted (approximately 76% viability). Concentrations
greater than 160µM were also analyzed, however, these higher
concentrations led to sorafenib visibly falling out of solution.
Therefore the CC50 was determined to be greater than 160µM
(Figure 3A). To determine the EC50, two-fold serial dilutions of
sorafenib from 20 to 0.625µM were used to pre- and post-treat
Vero cells infected with MP12-Luc (Figure 3B). The percentage
of luciferase reporter activity as compared to DMSO control
was calculated and the EC50 determined to be 6.4µM. To
further validate the EC50 measurement, a similar experiment
was performed using rMP12 infection in which plaque assays
were used to determine the reduction in virus titers (Figure 3C).
Within this context the EC50 was shown to be 3.9µM. Using a
CC50 value of 160µM, the SI of sorafenib was determined to
be>31.74. For comparison purposes, ribavirin has been reported
to have a SI of>70 for RVFVMP12 (Furuta et al., 2013).
Sorafenib affects Multiple Stages of RVFV
Lifecycle
In order to gather more information about which stage of the
virus life cycle sorafenib affects, a time course was performed
using qRT-PCR to measure accumulation of viral RNA from
cell lysates (intracellular RNA, Figure 4A) and supernatants
(extracellular RNA, Figure 4B). No difference in viral RNA levels
between DMSO and sorafenib treated samples was observed at
2 hpi, suggesting that sorafenib does not impair RVFV entry.
A difference in viral RNA levels was detected as early as 4 hpi
(Figure 4A). There continued to be only a small increase in
intracellular viral RNA levels in sorafenib treated samples over
time compared to the exponential increase in DMSO treated
samples. This dramatic delay suggests that viral RNA production
may be impaired by sorafenib. The extracellular genomic copies
in sorafenib treated cells do not significantly change from 0 to
24 h (Figure 4B). The lack of extracellular viral RNA output may
simply be a consequence of the decreased of intracellular viral
RNA production. However, it is important to note that there
was approximately 1.5 log increase in intracellular viral RNA
from sorafenib-treated samples observed over time, without a
corresponding increase in extracellular RNA levels. These data
suggest that an additional virus life cycle step, possibly virus
assembly or egress, may be impaired.
Next, a time of addition study was performed where sorafenib
was added to cells at various times relative toMP12-Luc infection
(Figure 4C). Lysates collected at 24 hpi were analyzed for
Renilla luciferase reporter activity. No inhibition was noted when
cells were pretreated with sorafenib (−1 treatment), supporting
the notion that sorafenib does not interfere with viral entry.
Furthermore, sorafenib was able to reduce luciferase reporter
activity when added to the cells as late as 6 hpi, suggesting that an
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TABLE 2 | FDA-approved drugs that significantly inhibited MP12 1NSs-Luc without reducing cellular viability.
Target Drug name Infection vs. p-Value Viability (%) References
DMSO (%)
Growth factor receptor inhibitors
Sorafenib (Nexavar) 7 0.0001 103 Adnane et al., 2006
Masitinib (AB1010) 16 0.0002 89 Humbert et al., 2009
OSI-420 (Desmethyl Erlotinib) 35 0.0006 86 Zerbe et al., 2008
Pazopanib HCl 39 0.0007 97 Welsh and Fife, 2015
Microtubule assembly and disassembly modulators
Paclitaxel (Taxol) 22 0.0003 85 McGrail et al., 2015
Vincristine 39 0.0009 87 LaPointe et al., 2013
Docetaxel (Taxotere) 55 0.0027 108 Mizuuchi et al., 2015
Synthetic estrogen receptor modulators
Toremifene Citrate (Fareston, Acapodene) 28 0.0004 119 Hariri et al., 2015
Tamoxifen Citrate (Nolvadex) 32 0.0005 102 Vogel, 2015
Fulvestrant (Faslodex) 57 0.0039 84 Lai et al., 2015
Anti-parasitic
Fenbendazole (Panacur) 19 0.0001 100 Samaee, 2015
Ivermectin 43 0.0015 95 Arndts et al., 2015
DNA synthesis inhibitor
Gemcitabine HCl (Gemzar) 14 0.0002 81 Sai et al., 2015
Teniposide (Vumon) 43 0.001 95 Clark and Slevin, 1987
Antifungal agent
Itraconazole (Sporanox) 26 0.0003 88 Feldstein et al., 2015
Clotrimazole (Canesten) 67 0.0079 94 Chung et al., 2015
Histamine H1 antagonist Clemastine Fumarate 37 0.0008 119 Apolloni et al., 2014
Calcium antagonist Manidipine dihydrochloride (CV-4093) 37 0.0008 140 Rizos and Elisaf, 2014
Nucleoside analog Floxuridine 55 0.0042 108 Vivian and Polli, 2014
Noradrenaline reuptake inhibitor Maprotiline hydrochloride 59 0.0006 84 Chew and Ong, 2014
Serotonin receptor agonist Quetiapine fumarate (Seroquel) 59 0.001 81 Pisu et al., 2010
additional late stage event such as virus assembly or egress could
be inhibited.
To test whether viral egress was impacted, the amount of
intra- and extracellular infectivity was examined at both early
(8 hpi) and late (24 hpi) timepoints in both HSAEC and Huh7
cells after rMP12 infection (Figure 5). In addition to sorafenib
treatment we also included ribavirin, a general inhibitor of viral
RNA dependent RNA polymerases (Arias et al., 2008). Inclusion
of ribavirin would allow us to account for inhibitor effects on
viral RNA replication alone. In both cell types early in RVFV
infection, both sorafenib and ribavirin treatment decreased
the amount of intracellular infectivity by several orders of
magnitude (Figures 5A,B). This results in a subsequent decrease
in detectable virus in media supernatants (i.e., extracellular
fraction). At 24 hpi, this pattern starts to alter. In the case of
ribavirin the amount of intra- and extracellular virus increases
slightly in HSAECs while in Huh7 cells levels remain comparable
to the 8 h timepoint. Thus if the block to viral RNA replication
alone starts to ease (as in the case of HSAEC cells) virus egress
is not impeded. However, after treatment with sorafenib, an
increase in the intracellular infectivity was observed especially
in Huh7 cells. Comparatively, the percentage of intracellular
infectivity (relative to the total infectivity) appears to shift with
prolonged sorafenib treatment to a significant degree in Huh7
cells (Figure 5C). Collectively these data implicate two points
within the RVFV lifecycle as targets for sorafenib inhibition,
replication and egress.
Computational Model of RVFV Infection
To provide data for a computational model, the growth of
RVFV MP12 in vitro with and without sorafenib treatment was
characterized (summarized in Figure 6A). HSAECs were pre-
treated with either DMSO or sorafenib and then infected with
RVFV at an MOI of 0.1. After 1 h incubation, the inoculum was
removed and the wells were washed with PBS to remove free
virus (inoculum and washes are referred to as unabsorbed virus
in Figure 6A). Thereafter, the respective drug media (or vehicle
control) was put back onto the wells and culture supernatants
were collected and viral titers were determined by plaque assay.
As shown, sorafenib prevented an increase in viral titers over the
entire experimental time course.
A computation model of RVFV infection was developed that
included 4 variables and 5 parameters (seeMaterials andMethods
Section for details). A schematic of the model is shown in
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Figure 6B. Model results obtained using these initial conditions
and parameter values (as discussed in Materials and Methods
Section) are shown in Figure 6C. As shown, there is excellent
agreement between themodel and actual pfu/ml data. Indeed, the
model predictions at 8, 16, and 24 hpi were 5.75×101, 4.85×105,
and 1.02× 106 pfu/ml, respectively, and the actual pfu/ml data at
these time points (from Figure 6A) were 3.10× 103, 1.40× 105,
and 1.05× 106 pfu/ml. To account for biological restrictions, the
minimum pfu/ml value was bounded to 1 in the data plotted on a
log10 scale (Figure 6C). Additionally, 700 pfu/ml was subtracted
from all data points prior to plotting Figure 6C to account for
background levels of virus detected in the culture supernatant
FIGURE 2 | Sorafenib reduces RVFV replication in multiple cell types.
(A) Vero, (B) HSAEC, (C) Huh7 cells infected with rMP12 (MOI 0.1) or (D) Vero
cells infected with BSL-3 RVFV strain rZH548 (MOI 0.1) were incubated with
either DMSO or sorafenib as described above (Figure 1). Media supernatants
were collected 24 hpi and infectious viral titers analyzed by plaque assay. The
average and standard deviation of three biological replicates are plotted.
*p ≤ 0.01.
at all time points. These background levels are not related to
the infection dynamics, but are experimental artifacts that are
primarily the result of (i) virus particles settling on plastic
rather than cells that are easily washed off, (ii) particles that are
loosely associated with cell surfaces that become dislodged during
washing, and (iii) from HSAECs (with internalized viruses) that
are actually dislodged during washing. Including this background
level of virus has negligible impact on the later time points
where the titers are 105 pfu/ml or higher, but in contrast these
artifacts can greatly distort data at the early time points where
very little de novo synthesized virus is expected to be in the culture
supernatant.
Because these results suggest the model captured the natural
infection dynamics very well, the model was used to begin
addressing what step in the virus life cycle could be altered
by sorafenib. To this end, pfu/ml over time was modeled after
each parameter was manually adjusted. This modeling technique
is a type of preliminary sensitivity analysis and begins to test
different hypotheses for the drug mechanism of action. As an
example, if sorafenib blocks infection, then manually decreasing
the infection rate in themodel (running themodel with a lower b)
would simulate that mechanism and viral titers in the model
output would, in turn, be decreased and match those observed
in actual experiments. In contrast, if running the model with
a lower b had no effect on the model output during the first
24 h, then this observation would support a hypothesis stating the
mechanism of action of sorafenib is not at the infection step of the
virus life cycle. Table 3 summarizes viral output from the model
(pfu/ml at 24 h) when each parameter is adjusted by at least two
orders of magnitude. As shown, decreasing HSAECs growth rate
(g) by 2 orders of magnitude (from 0.742×10−3 to 0.742×10−5)
had no effect on virus titers at 24 h. Likewise, (i) decreasing the
infection rate (b) by 2 orders of magnitude, (ii) decreasing the
death rate (d) by 2 orders of magnitude, or (iii) altering the
delay time (1/l) had little to no observable effect on viral titers
FIGURE 3 | Selective index of Sorafenib. (A) Serial 2-fold dilutions (160,
80, 40, 20, 10, 5, 2.5, 1.25, and 0.625µM) of Sorafenib were used for
treatment of Vero cells. After 24 h, cell viability was assessed and plotted as
percentage of the control, DMSO alone. Mean and standard deviations are
plotted from three biological replicates. Non-linear regression stastics was
applied, with the constraint that bottom of the span was to set to less than
10%, to determine the CC50. (B,C) Serial 2-fold dilutions (20, 10, 5, 2.5,
1.25, and 0.625µM) of sorafenib were used for treatment of Vero cells
infected at a MOI 0.1 with either MP12 1NSs-Luc (B) or rMP12 (C) viruses.
After 24 hpi, luciferase activity (B) or infectious virus titers (C) were
measured. For luciferase activity, all treatments concentrations were
normalized as a percentage of the control, DMSO alone. For both analyses,
the mean and standard deviations from three biological replicates are plotted.
Nonlinear regression statistics was applied and the corresponding EC50
determined. The EC50 of sorafenib for MP12 1NSs-Luc and rMP12 were
6.4 and 3.9µM, respectively.
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FIGURE 4 | Sorafenib affects an early stage of infection. (A,B) HSAECs
were pre-treated, infected and post-treated with either DMSO or sorafenib.
Supernatants and lysates in RLT buffer were collected at the indicated times
post-infection. RNA was extracted from all samples and a qRT-PCR was
performed to determine viral genomic copies. The average and standard
deviation of three biological replicates are plotted. (C) HSAECs were treated at
various times relative to MP12 1NSs-Luc infection (1 h pre-treatment, at the
end of 1 h infection, at 2, 4, 6 hpi, both pre-treated and post-treated). Lysates
were collected at 24 hpi and analyzed for luciferase activity. Data is graphed in
percentage RLU of the DMSO control. *p ≤ 0.01.
at 24 h. However, in contrast, viral titers at 24 h were dramatically
affected by decreasing the virus production rate (p). For example,
decreasing p by an order of magnitude (from 0.531 to 0.0531)
resulted in 0 pfu/ml at 24 h. A similar sensitivity-type analysis was
done on model initial conditions and results suggest viral titers
24 hpi are not sensitive to changes in variable initial conditions
(see Supplemental Data for additional details). Collectively, these
observations support a hypothesis where sorafenib prevents virus
accumulation in this tissue culture supernatant by primarily
FIGURE 5 | Increase in rMP12 intracellular infectivity after sorafenib
treatment. (A) HSAECs and (B) Huh7 cells infected with rMP12 (MOI 0.1)
were either left untreated, or treated with DMSO, 10µM sorafenib, or 82µM
ribavirin as described previously. Intra- and extracellular infectivity per infection
as determined by plaque assay is plotted. (C) Total infectivity (i.e., sum of intra-
and extracellular infectivity) per infection was determined. The percentage of
intracellular infectivity relative to the total was plotted for all conditions. Means
and standard deviations for four biological replicates are plotted. Two Way
ANOVA comparing conditions within each cell background was performed
utilizing the Holm-Sidak correction for multiple comparisons. Those
comparisons that demonstrated significant differences between DMSO and
the other conditions at their respective timepoints are shown. ***p ≤ 0.001,
****p ≤ 0.0001.
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FIGURE 6 | Comparison between experimental data and the
computational model for HSAEC infection. (A) Virus in the culture
supernatant (2–24 hpi) after the addition of sorafenib (gray bars) or
DMSO-vehicle (black bars). Data are average pfu/ml ± standard deviations
and each bar represents three biological replicates. (B) Schematic of the
computational model showing uninfected HSAECs (U), early infected HSAECs
(E), infected virus-producing HSAECs (I) and Virus particles (V) (see text for
additional details). (C) Comparison between experimental data and model
results. Open circles are the DMSO-vehicle data reproduced from (A) and the
dashed line is pfu/ml data produced from the computational model using the
parameter values summarized in Table 1.
acting to prevent viral production within infected HSAECs
and/or viral particle release from infected cells. These conclusions
are in agreement with the data shown in Figure 4.
Loss of Raf Does Not Decrease RVFV Replication
Given that sorafenib was first discovered as a Raf inhibitor,
this kinase could be hypothesized to play a major role in the
TABLE 3 | Model results (pfu/ml at 24h) with adjusted parameter values.
Parameter value pfu/ml at 24h post infection
– Actual data (from Figure 6A) – 1.050× 106
HSAEC GROWTH RATE (g)
0.742× 10−3** 1.016× 106
0.742× 10−4 1.014× 106
0.742× 10−5 1.013× 106
INFECTION RATE (b)
0.195** 1.016× 106
0.0195 1.016× 106
0.00195 1.015× 106
DELAY (LAG) TIME (1/l)
1 h 1.311× 106
4 h** 1.016× 106
6 h 8.391× 105
8 h 6.899× 105
16 h 3.253× 105
DEATH OF HSAECs (d)
0.222 2.295× 105
0.0222** 1.016× 106
0.00222 1.227× 106
0.000222 1.251× 106
VIRAL PRODUCTION RATE (p)
0.931 5.278× 105
0.531** 1.016× 106
0.0531 <1
0.431 7.669× 105
0.331 5.194× 105
0.131 3.223× 104
** Parameter values that were obtained directly from data. These parameter values are
summarized in Table 2 and were used to produce the curve shown in Figure 6C.
viral lifecycle. To examine the dependency of RVFV infection
on Raf function, siRNA knockdowns of both B- and C-
Raf were performed followed by infection with MP12. To
make sure that the siRNA transfections resulted in a robust
knockdown of Raf, western blots probing for both isoforms
were performed. B- and C-Raf protein levels were greatly
reduced both individually and in combination (Figure 7A). After
knockdown, cells were infected with MP12 and infectious viral
titers determined at 8 and 16 hpi. A reduction in titers was
not observed between siRNA treated cells and control cells
(Figure 7B). To further confirm that kinase activity of Raf was
not required for RVFV infection, treatment with a sorafenib
analog, SC-1, was performed. SC-1 differs from sorafenib in
that SC-1 does not affect Raf kinase activity, but retains the
ability to inhibit signal transducer and activator of transcription
3 (STAT3) (Yang et al., 2008; Wang et al., 2013). Thus cells
treated with SC-1 will retain Raf kinase activity. SC-1 was
observed to inhibit RVFV replication between 2 and 3 logs,
which was similar to sorafenib inhibition (compare Figure 2
with Figure 7C). These data suggest that Raf kinase activity is
not the main anti-viral feature of sorafenib inhibition in RVFV
infection.
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FIGURE 7 | Loss of Raf does not inhibit RVFV replication. Targeted
siRNA was used to knockdown either B-Raf or C-Raf alone or in
combination. (A) Western blots show levels of B- and C-Raf proteins. β-Actin
was used as a loading control. (B) Cells with siRNA knockdown treatment
were infected with rMP12 at MOI 3. Supernatants were collected at 8 h and
at 16 hpi and plaque assays were performed. (C) Cells were pre-treated and
post-treated with SC-1 or DMSO and infected with MP12 MOI 0.1.
Supernatants were collected 24 hpi and a plaque assay was performed. The
average and standard deviation of three biological replicates are plotted.
*p ≤ 0.01.
In Vivo Effect of Sorafenib
Finally experiments were performed to examine whether
sorafenib exerted a similar influence on viral replication in vivo
as observed in vitro. First, the effect of sorafenib on uninfected
BALB/c mice was characterized to determine possible adverse
effects by drug treatment. Mice were treated with 20mg/kg,
40mg/kg, or solvent control by oral gavage and were monitored
daily for weight loss and changes in body condition. The
40mg/kg dose caused a small decrease in weight between Day
8 and 11 post-treatment, while the 20mg/kg dose matched
the control group weight very closely (Figure 8A). In order to
minimize toxicity while still maintaining efficacy of the drug,
30mg/kg of sorafenib was used to treat mice infected with RVFV
ZH501 daily for 10 days. Animals were monitored for 14 days
post challenge. Although a trend demonstrating that sorafenib
increased survival as compared to control animals was observed,
the difference was not statistically significant (Figure 8B). Viral
RNA levels in the spleens and livers (Figures 8C,D, respectively)
of infected animals were analyzed at 2, 3, and 4 days post-
infection (dpi), while day 4 spleen and liver samples were also
analyzed for viral titers by plaque assay (Figure 8E). Although
not statistically significant, these data demonstrate a trend toward
reduction in viral burden at day 4, indicating that sorafenib was
effective against RVFV in an in vivomodel.
Discussion
The aim of this study was to find a compound that is approved
by the FDA for human use and which would be effective
against RVFV infection. Repurposing currently approved drugs is
desirable as their safety profiles, bioavailability, and mechanisms
of action have been extensively studied. Also, in the event of
an outbreak, an FDA approved drug may be developed and
distributed by amanufacturer that is already producing it with far
less delay when compared with a newly discovered compound.
A wide range of compound classes that were effective at
inhibiting RVFV were identified. Some compounds however,
did have characteristics in common. For example, sorafenib
tosylate, masitinib, OSI-420 and pazopanib HCl are all growth
factor receptor inhibitors; paclitaxel, vincristine sulfate and
docetaxel affect microtubule assembly and disassembly; and
toremifene citrate, tamoxifen citrate and fulvestrant are synthetic
estrogen receptor modulators. Although none of these drugs are
commercially available to treat viral diseases, several of them
have been demonstrated to exhibit antiviral activity (Table S1):
sorafenib has been shown to improve survival of patients with
hepatitis-B virus-related hepatocellular carcinoma (Xu et al.,
2015); gemcitabine has potent anti-HIV-2 activity (Beach et al.,
2014) as well as anti-influenza A activity (Denisova et al.,
2012); paclitaxel inhibits the spread of influenza A virus from
cell to cell (Roberts et al., 2015); itraconazole was identified
as an effective inhibitor of enterovirus infections (Gao et al.,
2015); toremifene has been shown to act as a potent ebola
virus (EBOV) inhibitor (Johansen et al., 2013). Tamoxifen
exhibited extensive antiviral activities toward herpes simplex
virus-1 (Zheng et al., 2014). Pazopanib blocked Andes virus-
induced endothelial cell permeability and prevented hantavirus
pulmonary syndrome (Gorbunova et al., 2011). Ivermectin was
able to reduce Venezuelan equine encephalitis virus replication
(Lundberg et al., 2013). All serotypes of dengue virus, as well as
West Nile virus were highly sensitive to floxuridine (Fischer et al.,
2013).
The drug candidate that proved most effective against RVFV
was sorafenib. Sorafenib (Nexavar) is an orally active multi-
kinase inhibitor that is FDA-approved for the treatment of
hepatocellular carcinoma and renal cell carcinoma. It targets
a number of receptor tyrosine kinases, but was primarily
identified as a C-Raf inhibitor (Adnane et al., 2006). Sorafenib
functions by directly blocking the autophosphorylation of
receptor tyrosine kinases (RTKs). These RTKs include VEGFR
(vascular endothelial growth factor receptors) 1, 2, and 3,
PDGFRβ (platelet derived growth factor receptor), c-Kit and RET
which are all pro-angiogenic and are involved in tumorigenesis
(Keating and Santoro, 2009). In addition, sorafenib inhibits
downstream Raf kinase isoforms including wild-type C-Raf, B-
Raf, and the mutant B-Raf V600E. It interacts with Raf kinases
by stabilizing the DFG motif (the “Asp-Phe-Gly” motif at the
N terminus of the activation loop, Treiber and Shah, 2013) in
an inactive conformation (Wilhelm et al., 2006). Furthermore,
sorafenib inhibits tumor cell proliferation by targeting the
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FIGURE 8 | Sorafenib reduces viremia while increasing survival in
RVFV-infected mice. (A) Uninfected BALB/c mice were treated with
20mg/kg, 40mg/kg, or solvent control by oral gavage. Animals were
monitored daily for weight loss over 14 days. Percentage of weight
maintained (relative to starting weight) was determined. Data plotted
represents the mean values and standard deviations of three animals per
treatment group. (B) BALB/c mice were infected with 1× 103 pfu RVFV
ZH501 by sub-cutaneous injection. Mice were pretreated 2 h prior to
infection, and each day post infection with 30mg/kg of sorafenib or solvent
control via oral gavage. Animals were monitored for 14 days post challenge
and survival curves determined. Data plotted represents 10 animals per
treatment group. (C) thru (E) Mice infected and treated as described above
were sacrificed at 2, 3, and 4 days post infection (dpi). Livers and spleens
were harvested. RVFV genomic copies within the spleen (C) or liver (D) were
quantified by qRT-PCR for each day. Infectious viral titers (E) were
determined for day 4 only by plaque assay. Data plotted represents means
and standard deviations from three animals per condition. Filled in circles and
open circles represent sorafenib and solvent controls respectively.
mitogen-activated protein kinase (MAPK) pathway at the level
of the Raf kinase (Ravikumar et al., 2011). Overall, sorafenib
influences tumor cells and cells of the tumor vasculature.
The potential to repurpose FDA approved drugs has been
evaluated for EBOV (Johansen et al., 2013) and a number of
biological threat agents including Bacillus anthracis, Francisella
tularensis, Coxiella burnetii, and ebola, Marburg, and Lassa
fever viruses (Madrid et al., 2013). Selective estrogen receptor
modulators (SERMs) were identified as having antiviral effects
against EBOV. SERMs were capable of inhibiting EBOV even
in cells that were deficient in estrogen receptors, suggesting
that these drugs were not acting through their established
targets (Johansen et al., 2013). Likewise, the classical mechanism
of action of sorafenib appears to be unnecessary for RVFV
inhibition. This was demonstrated through siRNA depletion of
Raf having little to no effect on viral replication. It should be
noted that these results do not definitively exclude Raf from
having an influence on RVFV replication, as siRNA depletion
experiments do not result in a complete loss of B- or C-Raf
protein expression. There is also the possibility that sorafenib
could be influencing receptor tyrosine kinase activity such as
VEGFR or PDGFR, which was not addressed here. However, SC-
1, which is a sorafenib analog lacking kinase-inhibitory activity,
decreased RVFV to levels comparable to sorafenib. These results
support the hypothesis that non-classical targets of sorafenib are
important for RVFV replication.
Recently, signal transducer and activator of transcription
3 (STAT3) was identified as an additional target of sorafenib
(Yang et al., 2008). Phosphorylation of STAT3 was inhibited
following sorafenib treatment, which was associated with
inhibition of cell proliferation and induction of apoptosis
in medulloblastomas. Both sorafenib and SC-1 operate by
preventing STAT3 phosphorylation and thus preventing its
subsequent activation. STAT3 phosphorylation is inhibited by
directly activating the upstream protein tyrosine phosphatase Src
homology 2-domain containing tyrosine phosphatase 1 (SHP-1)
(Liu et al., 2013). Therefore, proteins downstream of SHP-1 may
be influencing RVFV replication. SHP-1 affects a vast number of
proteins apart from STAT3. These include Akt, NF-κB, ERK, and
JNK (Chong and Maiese, 2007). As a result, unearthing a single
cellular target of sorafenib that RVFV is exploiting to propagate
its life cycle might prove to be challenging.
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Sorafenib was effective at inhibiting RVFV in vitro with an SI
of>31, but only demonstrated limited efficacy in a subcutaneous
mouse model of RVFV infection. There are a number of
possibilities that could explain the limited improvement in
animal survival observed. The half-life of sorafenib is quite long
(25–48 h) (Flaherty et al., 2008), thus a once a day dosing regimen
was chosen. Altering the dosing schedule and dosage amounts
could provide for improvement in animal survival. However,
the most significant contributing factor is that the target for
sorafenib inhibition in RVFV infected cells is non-canonical (as
discussed above). While sorafenib has potent activity against Raf
and receptor tyrosine kinases, the potency against the as yet to
be determined cellular target during RVFV infection is unclear.
Sorafenib target identification in the context of RVFV infection
is necessary to allow further refinement of sorafenib and/or
selection of additional lead candidates for drug development
efforts.
Mechanism of action and computational modeling studies
indicated that sorafenib influences at least two steps in the viral
infectious cycle, RNA synthesis and virus assembly/egress. The
degree to which viral egress is impacted appears to be cell type
dependent as shown when comparing % intracellular infectivity
between HSAEC vs. Huh7 cells (Figure 5C). Whether, this is due
to differing levels of the protein targeted by sorafenib inhibition
in Huh7 cells or possible dual roles of this cellular factor in both
virus assembly and egress remains to be determined. Recently
Descamps et al. demonstrated that multiple steps of hepatitis C
virus infection were inhibited by sorafenib treatment, namely
entry and production of infectious viral particles (Descamps
et al., 2015). RVFV entry has been shown to be largely
caveola-mediated (Harmon et al., 2012). While caveola-mediated
endocytosis is a complex process regulated in part by tyrosine
kinases and phosphatases, RVFV dependence on these signaling
cascades is not entirely known. Thus, as sorafenib targets receptor
tyrosine kinases, the possibility of inhibiting viral entry is not
unexpected. However pre-treatment of cells with sorafenib had
no effect on RVFV replication and computational modeling
supports the idea that sorafenib has no impact on RVFV entry.
Furthermore, the siRNA experiments and SC-1 treatment suggest
that sorafenib likely acts independent of its tyrosine kinase
inhibitory activity. RVFV RNA synthesis was dramatically altered
following sorafenib treatment. However, these studies did not
differentiate between viral transcription or RNA replication as
the qRT-PCR assay utilized does not discriminate between RNA
species. Additional studies are necessary to determine if sorafenib
is influencing primary mRNA transcription, replication, or
secondary mRNA transcription. A number of cell based systems
have been developed to differentiate between primary mRNA
transcription and replication (Habjan et al., 2008; Klemm et al.,
2013) which will be useful for this analysis.
The computational model developed herein provided
additional evidence that sorafenib influences RVFV post entry
and results in a decrease in infectious virus released. The model
was fully parameterized using actual experimental data and
appeared to capture the infection dynamics quite well. Results
for our in vitro infection model suggested that HSAECs were
infected quickly following the addition of virus, but new viruses
were not released in the extracellular media until approximately
8 hpi. At that time, all HSAECs have become infected and shortly
thereafter all infected HSAECs are assembling new virus. When
the model was used to simulate and assess potential anti-viral
mechanisms associated with sorafenib, results suggested that the
inhibitor had no effect on virus uptake by HSAECs per se. Rather,
sorafenib was acting on infected HSAECs by either inhibiting
RNA production, preventing formation of mature intracellular
particles, or preventing their release. These conclusions agreed
well with additional data that showed sorafenib could exert its
effect when added up to 6 h post the start of infection, increased
intracellular infectivity (especially in Huh7 cells) at 24 hpi and
had no effect on viral RNA accumulation during the first 4 h of
infection. Future studies will focus on refinement of this model
to include additional steps of the virus lifecycle cycle to allow a
more detailed analysis to be performed and narrow down the
mechanism of sorafenib inhibition.
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